Weh H J, Zügel M, Wingberg D, Schwarz R, Zornig C, Dietel M, Hossfeld D K
Abteilung für Onkologie und Hämatologie, Universitätskrankenhaus Eppendorf, Hamburg.
Onkologie. 1990 Dec;13(6):448-52. doi: 10.1159/000216818.
Between 1982 and 1986, 38 patients with soft tissue sarcomas were treated with a combination of ADM/DTIC (group A), another 45 (group B) received ADM/IFO between 1986 and 1990. Clinical characteristics were comparable in both groups. Remission rate was 34% in group A and 43% in group B. Duration of remission was 10 months and median survival 13 months in both groups. Toxicity, especially myelotoxicity, was severe without marked differences between both groups. We conclude that adriamycin/DTIC and adriamycin/ifosfamide are both active regimens in metastatic soft tissue sarcomas, nevertheless, overall prognosis remains poor.
1982年至1986年间,38例软组织肉瘤患者接受了阿霉素/达卡巴嗪联合治疗(A组),另外45例(B组)在1986年至1990年间接受了阿霉素/异环磷酰胺治疗。两组的临床特征具有可比性。A组的缓解率为34%,B组为43%。两组的缓解期均为10个月,中位生存期均为13个月。毒性,尤其是骨髓毒性,很严重,两组之间无明显差异。我们得出结论,阿霉素/达卡巴嗪和阿霉素/异环磷酰胺在转移性软组织肉瘤中都是有效的治疗方案,然而,总体预后仍然很差。